tetano
Editor, Senior Moderator
Stem Cell Res Ther
. 2022 Feb 7;13(1):61.
doi: 10.1186/s13287-022-02743-0.
Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19
Kun Lu[SUP] #[/SUP][SUP] 1 [/SUP], Shi-Tao Geng[SUP] #[/SUP][SUP] 2 [/SUP], Shikai Tang[SUP] #[/SUP][SUP] 3 [/SUP], Hua Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wei Xiong[SUP] #[/SUP][SUP] 1 [/SUP], Fang Xu[SUP] #[/SUP][SUP] 1 [/SUP], Qijun Yuan[SUP] 1 [/SUP], Xian Xiao[SUP] 1 [/SUP], Renqiang Huang[SUP] 1 [/SUP], Haihui Liang[SUP] 1 [/SUP], Zhipeng Chen[SUP] 1 [/SUP], Chuanyun Qian[SUP] 4 [/SUP], Yang Li[SUP] 5 [/SUP], Songqing Wang[SUP] 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a highly infectious epidemic disease that has seriously affected human health worldwide. To date, however, there is still no definitive drug for the treatment of COVID-19. Cell-based therapies could represent a new breakthrough. Over the past several decades, mesenchymal stromal cells (MSCs) have proven to be ideal candidates for the treatment of many viral infectious diseases due to their immunomodulatory and tissue repair or regeneration promoting properties, and several relevant clinical trials for the treatment of COVID-19 have been registered internationally. Herein, we systematically summarize the clinical efficacy of MSCs in the treatment of COVID-19 based on published results, including mortality, time to symptom improvement, computed tomography (CT) imaging, cytokines, and safety, while elaborating on the possible mechanisms underpinning the effects of MSCs, to provide a reference for subsequent studies.
Keywords: Clinical efficacy; Coronavirus disease 2019; Immunomodulation; Mesenchymal stromal cells; Tissue repair.
. 2022 Feb 7;13(1):61.
doi: 10.1186/s13287-022-02743-0.
Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19
Kun Lu[SUP] #[/SUP][SUP] 1 [/SUP], Shi-Tao Geng[SUP] #[/SUP][SUP] 2 [/SUP], Shikai Tang[SUP] #[/SUP][SUP] 3 [/SUP], Hua Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wei Xiong[SUP] #[/SUP][SUP] 1 [/SUP], Fang Xu[SUP] #[/SUP][SUP] 1 [/SUP], Qijun Yuan[SUP] 1 [/SUP], Xian Xiao[SUP] 1 [/SUP], Renqiang Huang[SUP] 1 [/SUP], Haihui Liang[SUP] 1 [/SUP], Zhipeng Chen[SUP] 1 [/SUP], Chuanyun Qian[SUP] 4 [/SUP], Yang Li[SUP] 5 [/SUP], Songqing Wang[SUP] 6 [/SUP]
Affiliations
- PMID: 35130977
- DOI: 10.1186/s13287-022-02743-0
Abstract
Coronavirus disease 2019 (COVID-19) is a highly infectious epidemic disease that has seriously affected human health worldwide. To date, however, there is still no definitive drug for the treatment of COVID-19. Cell-based therapies could represent a new breakthrough. Over the past several decades, mesenchymal stromal cells (MSCs) have proven to be ideal candidates for the treatment of many viral infectious diseases due to their immunomodulatory and tissue repair or regeneration promoting properties, and several relevant clinical trials for the treatment of COVID-19 have been registered internationally. Herein, we systematically summarize the clinical efficacy of MSCs in the treatment of COVID-19 based on published results, including mortality, time to symptom improvement, computed tomography (CT) imaging, cytokines, and safety, while elaborating on the possible mechanisms underpinning the effects of MSCs, to provide a reference for subsequent studies.
Keywords: Clinical efficacy; Coronavirus disease 2019; Immunomodulation; Mesenchymal stromal cells; Tissue repair.